BFM
CLYM

Boothbay Fund Management’s Climb Bio CLYM Stock Holding History

Boothbay Fund Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Buy
182,645
+90,348
+98% +$933K 0.03% 647
2026
Q1 		$632K Buy
+92,297
New +$532K 0.01% 1207
2025
Q2 		– Sell
-53,662
Closed -$65.5K – 1833
2025
Q1 		$65.5K Hold
53,662
– – ﹤0.01% 1259
2024
Q4 		$96.6K Sell
53,662
-12
-0% -$43 ﹤0.01% 1295
2024
Q3 		$273K Buy
53,674
+22,964
+75% +$162K 0.01% 1293
2024
Q2 		$218K Buy
+30,710
New +$204K 0.01% 1262

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Boothbay Fund Management's CLYM Position: Q2 2026 in Review

Boothbay Fund Management increased its Climb Bio (CLYM) stake by 98% in Q2 2026, buying an estimated $933K and bringing the position to 182,645 shares worth $2.38M. The position accounts for 0.03% of the portfolio, ranked #647.

Boothbay Fund Management first reported a position in CLYM in Q2 2024 and has held it in 6 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Boothbay Fund Management held 182,645 shares of Climb Bio worth $2.38M as of Q2 2026.
  • Boothbay Fund Management bought 90,348 Climb Bio shares in Q2 2026, an estimated $933K.
  • Climb Bio made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #647 holding.
  • Boothbay Fund Management first reported a position in Climb Bio in Q2 2024 and has held it in 6 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.